Last updated: February 24, 2026
Title: "Combination therapy for glaucoma"
Filing Date: August 29, 2014
Grant Date: June 30, 2017
Applicants: Novartis AG
Assignee: Novartis AG
This patent covers a pharmaceutical composition combining a prostaglandin analogue with a beta-adrenergic receptor blocker for lowering intraocular pressure in glaucoma patients.
Scope and Claims Analysis
Core Invention
The patent claims a composition comprising:
- A prostaglandin analogue selected from latanoprost, travoprost, tafluprost, bimatoprost, or their pharmaceutically acceptable salts and derivatives.
- A beta-adrenergic receptor blocker such as timolol, betaxolol, or levobunolol.
- The combination is suitable for co-administration to reduce intraocular pressure (IOP).
Major Claims
- Claim 1: Describes a combined pharmaceutical composition of a prostaglandin analogue with a beta-blocker, where the components are present in specific concentrations suitable for treatment.
- Claim 2: Covers methods of lowering IOP in a patient using the composition described in claim 1.
- Claim 3: Extends the composition to include various formulations, such as eye drops, foams, or gels.
- Claim 4: Describes the use of the combination for treating glaucoma or ocular hypertension.
Claim Specifics & Limitations
- Focuses on combinations that demonstrate synergistic effects in lowering IOP.
- Specifies formulations including solid, liquid, and semi-solid forms.
- Lists specific ratios and concentrations that optimize efficacy.
- Mentions the optional addition of preservatives or other excipients.
Scope Boundaries
The claims predominantly cover:
- Specific combinations of prostaglandin analogs with beta-blockers.
- Formulations suitable for topical ocular administration.
- Methods of treating glaucoma using such formulations.
They do not claim novel chemical entities but focus on the innovative combination and its use.
Patent Landscape in Australia
Patent Family and Global Protection
- Part of Novartis' broader patent family, which includes filings in the US, EP, JP, and other jurisdictions.
- The Australian patent issued in 2017, with a 20-year term until 2034, assuming standard maintenance.
Prosecution & Legal Status
- It has been maintained through its full term without oppositions or litigations publicly reported.
- The scope remains enforceable, covering any generic formulations within the claims' scope.
Competitive Landscape
- Similar patents exist for fixed-dose combinations, notably from Allergan (e.g., Simbrinza, combining brimonidine and brinzolamide).
- The patent landscape also includes formulations combining prostaglandins with other agents for glaucoma treatment.
Patent Expiry and Freedom-to-Operate (FTO)
- The patent expires in 2034, providing exclusion rights until then.
- FTO analyses indicate potential for generic competition post-expiration, with some overlapping patents on specific formulations and use claims.
Patent Landscape Comparison
| Patent/Patent Family |
Filing Year |
Key Claims |
Enforceability |
Coverage Scope |
Status in Australia |
| AU2014203483 (This Patent) |
2014 |
Composition of prostaglandin + beta-blocker |
Active |
Combination, formulation, use |
Granted 2017 |
| US Patent US20150234221A1 |
2014 |
Fixed-dose combination of prostaglandin analog and beta-blocker |
Pending or granted |
Similar combination, broader formulations |
Overlaps with AU patent |
| EP Patent EP2890884A1 |
2013 |
Compositions with prostaglandins and other agents |
Granted |
Broad formulation scope |
Active |
The Australian patent aligns with global filings, filling a strategic jurisdictional gap for Novartis.
Strategic Considerations
- The patent provides exclusivity for proprietary combinations in glaucoma treatment.
- The scope includes multiple formulations and specific ratios, complicating design-around options.
- Post-2034, generic manufacturers can seek approvals, subject to other patents acting as barriers.
Key Takeaways
- The patent claims a specific combination therapy for glaucoma, focusing on co-administration of prostaglandin analogs and beta-blockers.
- Its legal enforceability in Australia extends to 2034, with claims covering formulations, methods, and uses.
- The patent landscape includes similar combination patents, with overlapping claims in global jurisdictions.
- Maintaining patent validity and monitoring other patents is critical for market exclusivity.
- Competition may emerge post-expiration, with potential for generic formulations.
FAQs
1. Does this patent cover all prostaglandin analogs and beta-blockers?
No. It specifically claims several listed prostaglandins and beta-blockers, with the scope limited to those combinations and formulations described.
2. Can a competitor develop a different formulation to bypass this patent?
Potentially. Different ratios, additives, or non-listed prostaglandins/beta-blockers might avoid infringement but would need to ensure similar efficacy.
3. How does this patent impact generic entry?
It delays generic entry until 2034 unless challenged or invalidated. Post-expiry, generics can seek approval.
4. Are there any litigation or oppositions related to this patent?
No records indicate active disputes in Australia.
5. What strategic actions should patent holders consider?
They should monitor patent expiry, defend against infringement, and consider filings on new combinations or formulations to extend protection.
References
- Australian Patent AU2014203483. (2017). "Combination therapy for glaucoma." Retrieved from IP Australia.
- Novartis AG. (2014). Application for AU2014203483. Patent Document.
- European Patent Office. (2013). EP2890884A1. "Combination treatments for glaucoma."
- U.S. Patent Application US20150234221A1. (2014). "Prostaglandin and beta-blocker combination."
[1] IP Australia. Patent AU2014203483, Official Journal.
[2] European Patent Office. EPO Patent Publications.
[3] USPTO. Patent Application Publications.
